Objective To assess the potential of screening for pre-eclampsia (PE) in a Chinese population.
Introduction
Randomized trial of aspirin versus placebo for prevention of preterm pre-eclampsia (ASPRE) confirmed earlier metaanalyses. [1] [2] [3] Prophylactic aspirin treatment initiated before 16 weeks was able to reduce the incidence of preterm preeclampsia (PE) by 62%. The ASPRE study protocol of regimented screening and prophylactic treatment of post-test high-risk pregnancies is a preventative strategy that could be adopted and implemented in other countries to further reduce the significant maternal and perinatal mortality and morbidity associated with the disease. [4] [5] [6] [7] A screen-and-treat approach would be a more focused protocol than current professional guidelines issued by the UK National Institute of Clinical Excellence (NICE) and the American College of Obstetricians and Gynecologists (ACOG). [8] [9] [10] Both guidelines are based on the presence of one or more clinical risk factors, resulting in up to 60% of pregnant women requiring prophylactic aspirin treatment compared with approximately 10% based on a multi-marker approach. 11, 12 Screening performance, however, is directly dependent firstly on whether prospective data is consistent with the patient characteristics and disease patterns assumed and expected within the risk calculation models, and secondly whether measurements collected in routine clinical practice are obtained with the same accuracy and reliability as those recorded within the highly controlled environment of a clinical trial. Any significant deviation in the underlying population characteristics or in measurements from the implemented risk model would be expected to result in significant deterioration in screening effectiveness by reducing either its sensitivity or its specificity.
Whilst the single-centre PE risk model developed by the Fetal Medicine Foundation (FMF, London, UK) is multiethnic, only 29 (1.8%) the women in the ASPRE study were of East Asian origins. Previous studies in East-Asians indicate that algorithms and models derived in non-East Asians need to be further adjusted. [13] [14] [15] Whether individual units in East Asia can also achieve a screening performance comparable to that of FMF-trained sonographers in the ASPRE study also remains unknown.
The objectives of this study were firstly to assess whether individual markers used to screen for PE in our Chinese population were consistent with those expected in the screening models; secondly, to develop predictive models for risk of early and late PE based on maternal characteristics; and lastly, to assess the potential PE screening performance using a multi-marker approach.
Methods

Subjects
Women attending the Hospital Authority first-trimester Down-syndrome screening test between August 2013 and April 2014, having had an ultrasound-confirmed viable singleton pregnancy, were invited to participate in the prospective study. Women consenting to participate were asked to provide a detailed clinical history, undergo an ultrasound scan to document their uterine artery (UtA) blood flow, and have their blood pressure measured. Gestational age was determined from the crown rump length (CRL) using a Chinese CRL-dating formula. 16 Pregnancy outcomes were obtained from our hospital electronic records or from the women directly if they did not deliver in our unit. Women who delivered in another unit were considered lost to follow-up if they remained uncontactable after three attempts over a 1-month period. Women were diagnosed as having had PE using the International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria, 17 specifically, maternal diastolic blood pressure ≥90 mmHg on at least two occasions 4 hours apart after 20 weeks' gestation with significant proteinuria determined either from a 24-hour urine analysis (>300 mg) or midstream dipstick assessment of "2+". To permit comparison with existing published studies, early and late onset PE were defined as PE before or after 34 weeks' gestation. 11, 18 All clinicians were blinded to all recorded additional measurements and all women were managed according to internally published departmental protocols. Under our existing protocol, women deemed at increased risk of developing PE based on maternal characteristics and past obstetric history were offered daily 80 mg aspirin.
The study was approved by the Institutional Review Board (Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee, reference numbers CRE-2009.450 and CRE-2014. 507).
Maternal assessment for pre-eclampsia
Women were asked whether they had a first-degree female family member who had experienced PE, details of their last delivery, whether they had PE or received prophylactic low dose aspirin or ant-hypertensives in the current pregnancy, and whether they had any autoimmune conditions such as systemic lupus erythematosus or antiphospholipid syndrome.
A single blood pressure reading was taken using a hospital-wide automated blood pressure monitor (Omron HEM 907; Omron Healthcare Co. Ltd, Kyoto, Japan) from each woman's left arm using a cuff size determined by the midarm circumference. Measurements were taken after resting in a seated position with the arm supported at the level of the heart. 19 Mean arterial blood pressure (MAP) was derived from the recorded systolic and diastolic blood pressures. Maternal height and weight were documented.
The uterine artery pulsatility index (UtA-PI) in the left and right uterine arteries was measured trans-abdominally in a sagittal plane at the level of the internal os, using a 2 mm gate and a <30°angle of insonation, in accordance with the FMF protocol. 20, 21 UtA-PI measurements were taken only when the UtA-PSV exceeded 60 cm/second. The left and right UtA-PI measurements were used to determine both the lowest and mean UtA-PI for each pregnancy. All sonographers performing uterine artery assessment were accredited by the FMF and, before the study commenced, had undergone a 4-month uterine artery UtA-PI quality assurance assessment to determine each individual's UtA-PI central tendency and dispersion, using target plots and CUSUM charts as described by Ridding et al. 22 Serum was extracted from blood samples taken at the same visit and kept at À80°C pending analysis. Our previous study indicated that PlGF levels in frozen samples were stable for at least 3 years. 23 After all deliveries had occurred, the stored samples were thawed and levels of placenta growth factor (PlGF) determined using the PlGF-123 assay (PerkinElmer Inc., Turku, Finland) with the Auto-DELFIA platform (PerkinElmer Inc., Turku, Finland). PAPP-A levels determined at the time of performing the women's Down syndrome risk assessment were retrieved from Laboratory Information System. PAPP-A levels were determined with the AutoDELFIA platform. The intra-and inter-assay coefficients of variation for all quality control samples for both PAPP-A and PlGF were <4%. Serum samples from all women developing PE were recovered whilst non-PE pregnancies were randomly selected from among the remaining pregnancies until the pre-planned minimum sample size had been achieved.
Sample size
The incidence of PE in our unit between 1995 and 2009 was 1.7%. 24 A minimum sample size of 1037 women with measurements for MAP, UtA-PI and PlGF would be needed to determine whether a screening test for PE had a minimum AUROC of 0.7 (power of 80%, alpha of 5%, expected PE: non-PE ratio of 1:58). 25 A minimum AUROC of 0.7 was chosen because previous studies indicated that screening using maternal risk factors plus MAP had an AUCROC of 0.76 when screening for early onset PE, whereas other combined marker combinations had a higher AUCROC. Before the start of the study recruitment, it was anticipated that some women would be prescribed prophylactic aspirin in accordance with our departmental protocol, potentially reducing the incidence of PE. In anticipation of this effect, it was decided that all women with PE within the recruited cohort would be selected and that non-PE women would be randomly chosen from the remaining non-PE pregnancies to achieve the minimum sample size. Funding was available to perform up to 1140 PlGF tests.
Statistical analysis
Deviation of unaffected distribution from expected levels To assess the MAP, lowest and mean UtA-PI and PlGF measurement log distributions in non-PE pregnancies were expressed as multiples of the gestational median (MoM) and adjusted for maternal and pregnancy characteristics. MoM were determined firstly using models reported by Wright et al., 26 and secondly from multivariate models developed from unaffected pregnancies in our study cohort. One-sample t-tests were performed to determine if measured log 10 distribution means deviated significantly from an expected mean of zero. Paired t-tests were performed to determine if the difference in MoM derived using the models of Wright et al. 26 and our Chinese-specific models were statistically significant.
Comparison of a priori risk of pre-eclampsia Individual women's a priori risks of early-and late-onset PE were determined using two published models, one based on cumulative risks and a second based on risks derived from multivariate logistic models. 18, 26 A multivariate logistic regression model for a priori risk of early, late, and any pre-eclampsia using backward stepwise elimination was also developed from our study cohort for comparison. ROC curves were constructed and differences in the AUCROC were assessed to determine if they were statistically significant. 27 Comparison of a posteriori risk of pre-eclampsia Women's a posteriori risks for early and late onset PE were derived by combining their a priori risks with the likelihood ratios (LR) derived from their measured screening markers using Bayes theorem. Likelihood ratios for early and late onset PE were first derived using a published multivariate model reported by Cuckle, based on MAP, lowest UtA-PI, PAPPA, and PlGF, and a second model that replaces lowest UtA-PI by mean UtA-PI. 28 Cuckle reported that a meta-analysis-based risk model using MAP, lowest UtA-PI, PAPP-A, and PlGF had detection rates (DR) of 95 and 53% for early and late onset PE, respectively, at a fixed 10% false positive rate (FPR) based on LR alone, and 97 and 71% after incorporating patient characteristics. 28 A Monte Carlo simulation was performed using the risk model parameters reported by Cuckle, and detection rates (DRs) for 10% FPR were compared with those reported by Cuckle to ensure that risk model parameters had been accurately transposed to our risk calculation software. 28, 29 Screening performance was determined for fixed false positive rates (FPR) and DRs.
Analysis was performed using the Statistical Package for Social Sciences (SPSS) for Windows version 22 (SPSS, IBM, Armonk, NY, USA) and STATA SE12 (StataCorp LLC, College Station, TX, USA). A priori, a posteriori risks, and LR were determined using in-house software.
Results
A total of 3330 Chinese women underwent blood drawing, assessment of their UtA-PI, and had their blood pressure measured. Thirty women (0.9%) developed PE, 9 (0.3%) of which had PE before 34 weeks of gestation. We randomly selected 1054 women from the remaining 3300 non-PE women after using PlGF tests to perform analyser calibration and assay quality control assessments. There were no statistically significant differences in maternal age at delivery (P = 0.94), height (P = 0.37), weight (P = 0.51), BMI (P = 0.59), nulliparity (P = 0.34), primigravida (P = 0.44), family history of PE (P = 0.13), SLE (P = 0.19), history of aspirin or anti-hypertensive use (P = 0.18), smoking (P = 0.79), spontaneous conception (P = 0.26), gestational age at ultrasound scan (P = 0.96), CRL (P = 0.88), NT MoM (P = 0.91), PAPP-A MoM (P = 0.46), Free beta hCG MoM (P = 0.58), adjusted Trisomy 21 term risk ≥1:250 (P = 0.64), gestational age at delivery (P = 0.94), birthweight (P = 0.93) and pregnancy outcome (P = 0.2) between those randomly selected and not selected from the available non-PE pregnancies. Table 1 reports the maternal obstetric and pregnancy characteristics of the 1054 non-PE and 30 PE women used in subsequent statistical analyses. Women who developed PE were on average 2.5 years older, with half being of advanced maternal age (≥35 years); they were 2 cm shorter in height, 3.6 kg heavier (resulting in larger BMIs), and delivered a 1000 g lighter fetus 22 days earlier than women who did not develop PE.
Comparison of distributions relative to expected values in PE and non-PE pregnancies Table 2 summarizes the central tendency and variance of the log 10 MoM distributions of each screening marker in women who did not have PE. MoM were determined using multivariate models constructed from our enrolled patients (reported in Table S1) versus that obtained using pre-existing multivariate models described by Wright et al. 26 Onesample t-tests indicated that log 10 MoM distribution means determined using Wright et al. models deviated significantly from the expected values for MAP (P < 0.0001) in both the lowest and mean UtA-PI (P < 0.0001), but not PlGF (P = 1.0). One-sample t-tests indicated that log 10-MoM distributions determined using local Chinese models all had means not significantly different from zero (P = 1 for all), a requirement for the determination of PE risk. Paired t-tests confirmed that MAP MoM determined using the Wright et al. model were significantly higher than those using our local Chinese model, and that UtA-PI MoM (P < 0.0001) were lower and PlGF MoM were not significantly different. Table 3 summarizes the log 10 MoM distribution of each marker in women who developed PE. The median UtA-PI MoM in our local cohorts of early and late onset PE were 1.19 and 1.04 MoM, respectively, %26% and %15% lower than those reported in the same groups in previous studies. 30, 31 Overall, both mean and lowest UtA-PI MoM in our PE pregnancies were significantly lower (all: t = À3.59, P = 0.002; early: t = À8.60, P = 0.001; late: t = 0.99, P = 0.33), while PIGF MoM were significantly higher than reported values in PE pregnancies. 30, 31 The observed median PlGF MoM level was similar to 0.71 MoM in PE pregnancies observed in our earlier study. 32 MAP MoM distribution in PE pregnancies was not significantly different (P > 0.05).
Comparison of pre-eclampsia screening performance Table 4 reports AUROC and screening sensitivity for a fixed 10% FPR when screening for any, early, or late onset PE using models reported in Table S2 . Differences in AUROC between our Chinese model and that of Poon Had we screened for early and late onset PE using the screening model described by Cuckle, we would have achieved detection rates of only 72 and 58%, respectively, for a 10% FPR compared with the 97 and 71% reported by Cuckle. 28 
Discussion
Main findings
Firstly, the incidence of PE in our Chinese study population was 0.9%, 50% lower than initially anticipated. Secondly, marker MoM distributions using our Chinese models did not deviate significantly from 1 MoM. Had we determined MoM using published FMF models, the estimated risks for PE would have been inaccurate as the MAP and the lowest and mean UtA-PI MoM distributions in non-PE women deviated significantly from those assumed in the risk model. Had we screened for early onset PE using Cuckle's model, 28 
Strengths and limitations
The strengths were that few pregnancies were lost to follow-up and that all sonographers were accredited by the FMF and underwent UtA-PI quality assurance assessment. Study limitations were that the rate of PE was lower than anticipated and lower than the 1.4-1.6% observed in two previous epidemiological studies performed in same unit. 34, 35 We believe the reduced incidence was due to the introduction of a departmental protocol to offer prophylactic aspirin to women with a past history of PE. Other predictors such as mode of conception, inter-pregnancy interval, and presence/absence of autoimmune disease reported in other studies as significantly increasing a priori risk of maternal PE were not assessed. 8, 18, 26, 36 Alternative blood pressure measurement protocols and inter-arm blood pressure differences have been reported. 37, 38 The study of Poon et al. 38 would suggest, however, that overall screening performance using MAP determined from either the left or right arm, or the average of both arms was not significantly different. Lastly we used an automated blood pressure monitor, validated by the British Hypertension Society (BHS) but not for use in pregnancy. 39 The current BHS protocol only validates devices after 20 weeks of gestation, 40, 41 whereas PE screening is performed at 12 weeks.
Interpretation
Our study highlights the potential difficulties in implementing a screening program for PE. Whilst screening is reported as being able to identify over 90% of early onset PE, we were unable to do so even though we had ensured that all sonographers were accredited and performed UtA-PI measurements in accordance with the FMF protocol. We believe that under-measurement of UtA-PI, similar to that observed for nuchal translucency, 42 is the mostly likely Table 3 . Summary of the distribution of Log 10 marker multiples of gestational median (MoM) distributions in subjects who had pre-eclampsia using transformation models developed from enrolled subjects who did not have pre-eclampsia Log 10 MoM in pre-eclamptic pregnancies All pre-eclampsia (n = 30)
Early onset (n = 9) Late onset (n = 21) reason for the reduced screening sensitivity. Uterine artery pulsatility index is the single most important screening marker in the current risk model. The Mahalanobis distances for lowest and mean UtA-PI were markedly lower than those reported by Cuckle. 28 Further evidence for under-measurement is the median MoM of the lowest and mean UtA-PI MoM distributions in non-PE pregnancies when we determined MoM using the model of Wright et al. 26 Both were significantly lower than one. It is thus possible that UtA-PI measurements in our study were taken at a distal site. Ridding et al. 43 demonstrated that UtA-PI is sampling-site dependent. UtA-PI and PSV readings in their study were respectively 14.9 and 17.4% lower when measured at a site just 3 cm distal to that of readings taken at the level of the internal os. A follow-up study conducted at our unit both confirmed Ridding et al. findings as well as demonstrating that UtA-PI measurements taken by sonographers in our present study were consistent with UtA-PI measurements 2 cm distal to the internal os by a sonographer who underwent training and mentorship at the FMF. 43, 44 The UtA-PI measured by the FMF trained sonographer were respectively %8%, 15-17%, and 21-24% lower than those taken at the level of the internal os when measured 1, 2, and 3 cm distally. 44 Relying on UtA-PSV > 60 cm/second to ensure measurements are taken at the level of the os and not at other locations may not be adequate. Mean UtA-PSV readings in the Ridding et al. study (81 cm/second) at the 3 cm distal site were similar to the 83.6 cm/second we observed in our study. 43 One alternative would be to assess the UtA-PI using a transverse as opposed to the current sagittal approach as this would allow simultaneous viewing of both uterine arteries either side of the internal os, and the probe could then be tilted left and right without needing repositioning. 45 This may also further reduce potential inter-sonographer differences. There was a greater than 10% difference in UtA-PIs measured using the sagittal technique by two experienced sonographers, one trained at the FMF and the other, also accredited by the FMF and with over 15 years of experience. 44 One confounding factor in our cohort study was that women with previous history of PE were prescribed daily aspirin to prevent recurrence. Only 1 of the 25 women with previous history of PE developed PE, potentially explaining why the observed PE incidence rate was lower than anticipated. Regional variation in hypertensive disorder rates in China has been reported. The historical incidence rates for PE in our unit ranged from 1.4 to 1.6%, lower than the 2.1% reported across 14 provinces in mainland China. 34, 35, 46 Hypertension disorder rates among women in Southern China, who would be the most similar to women in Hong Kong, and among women in Central Chinese provinces are reported as being approximately 50-70% lower than the national rate and falling. 46 Selective prescribing of low dose aspirin would be an alternative explanation. Parks and colleagues earlier demonstrated that a policy of screening and offering daily aspirin to high risk women compared to no treatment reduced early onset PE incidence by over 90%, a reduction even greater than that observed in the ASPRE study. 1, 47, 48 A primary preventive approach in which high-risk pregnancies are offered prophylactic treatment before 16 weeks after screening would depend on whether reliable identification of at-risk pregnancies can be achieved and whether resources are available to carry out screening, particularly in middle income countries (MIC). The alternative to screening in MIC would be to offer 150 mg aspirin to all women on the assumption that aspirin carries a low-risk profile during pregnancy and is inexpensive compared with screening. This later approach presumes that women would be compliant even though they appeared to be symptom free. Treatment compliance is multi-factorial and found to be associated with age, gender, ethnicity, and medication side effects as well as the disease severity. 49 Treatment compliance is also higher when individuals feel susceptible to the illness or when they believe the treatment carries a perceived benefit, as illustrated in the ASPRE study where compliance rates were high. 49, 50 Assessment of a PE-screening and disease-prevention strategy in MIC in general and Asia in particular has not yet been performed. Pan-Asian studies similar to the SPREE (Screening programme for pre-eclampsia) and ASPRE studies are needed, not only to assess whether Asian centres can achieve screening performance figures reported in more established centres, but also to assess whether Asian women comply with their prescribed treatment. 51, 52 
Conclusion
Our study demonstrates the difficulties in implementing a program to screen for PE in Chinese women. Follow-up studies in our unit confirmed that a contributing factor to the lower-than-expected screening sensitivity is undermeasurement of the UtA-PI. 
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